Volcano Corporation (Volcano) has acquired the Xtract Thrombus Aspiration Catheter device line from Lumen Biomedical. The acquisition is in line with Volcano's plan to build a strategic portfolio of diagnostic and therapeutic tools to help patients with coronary artery disease including acute myocardial infarction (AMI).
Volcano said that the Xtract thrombus aspiration catheter supports the care of ST segment elevation myocardial infarction (STEMI). The catheter, with its patented, large single lumen design, circular right-angle tip and curved directional distal segment, delivers clot removal to re-establish blood flow quickly. The product line includes two sizes, with the larger size model offering the largest aspiration lumen of any aspiration catheter, for clot extractions.
Scott Huennekens, president and chief executive officer of Volcano, said: “Volcano is excited to fortify its commitment to be the leading and most-trusted partner for physicians when addressing patients with complex disease states that require thrombus aspiration. Since we began to distribute the Xtract catheter as it has been well-received by the interventional cardiology community.
“Consistent with our drive to continuously improve our product offerings, we have control over the product and rights to the design, and will be able to directly build upon the feedback we have received from our customers on how to further improve upon our approach to thrombus aspiration.”
Vince Burgess, group president of advanced imaging systems at Volcano, said: “Volcano could not be pleased about the new recommendation from the American College of Cardiology (ACC), American Heart Association (AHA), and Society for Cardiovascular Angiography and Interventions (SCAI) that aspiration thrombectomy, the procedure for which the Xtract device is designed, is reasonable in primary PCI for STEMI.
“This acquisition of the Xtract device line underscores how Volcano strives to be strategically ahead of the curve by providing physicians with the right technologies supported by the impactful clinical data. The acquisition of the Xtract product line is another example of our commitment to that strategy.”